Compare CASS & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASS | DRTS |
|---|---|---|
| Founded | 1906 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.2M | 609.0M |
| IPO Year | 1996 | N/A |
| Metric | CASS | DRTS |
|---|---|---|
| Price | $46.66 | $7.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $45.50 | $8.67 |
| AVG Volume (30 Days) | 65.7K | ★ 205.5K |
| Earning Date | 04-23-2026 | 05-18-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ 87.77 | N/A |
| EPS | ★ 2.61 | N/A |
| Revenue | ★ $190,750,000.00 | N/A |
| Revenue This Year | $0.81 | N/A |
| Revenue Next Year | $4.39 | $965.57 |
| P/E Ratio | $18.08 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $36.07 | $2.50 |
| 52 Week High | $47.43 | $8.60 |
| Indicator | CASS | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 65.32 | 53.59 |
| Support Level | $42.20 | $6.37 |
| Resistance Level | $47.43 | $7.75 |
| Average True Range (ATR) | 1.33 | 0.43 |
| MACD | 0.34 | 0.04 |
| Stochastic Oscillator | 85.20 | 69.60 |
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment, which provides transportation, energy, telecommunication, and environmental invoice processing and payment services to large corporations.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.